Amylyx Pharmaceuticals, Inc.
NASDAQ Global SelectTotal Valuation
Amylyx Pharmaceuticals, Inc. carries a market capitalization of 3.79B, placing it among publicly traded companies globally. Its enterprise value stands at 1.75B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.79B |
| Enterprise Value | 1.75B |
Share Statistics
Amylyx Pharmaceuticals, Inc. currently has 111.37M shares outstanding.
| Shares Outstanding | 111.37M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 8.36 |
| P/TBV Ratio | 8.36 |
| P/FCF Ratio | -15.09 |
| P/OCF Ratio | -15.07 |
Financial Position
Amylyx Pharmaceuticals, Inc. maintains a current ratio of 12.12, meaning it holds 12.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.12 |
| Quick Ratio | 11.86 |
| Debt / Equity | 2.20 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -74.73 |
| Return on Assets (ROA) | -66.25 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 46,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Amylyx Pharmaceuticals, Inc.'s stock has gained approximately 234.31373% over the past 52 weeks. The 50-day moving average sits at 24.23, while the 200-day moving average is 16.87.
| Beta (5Y) | N/A |
| 52-Week Price Change | 234.31373% |
| 50-Day Moving Average | 24.23 |
| 200-Day Moving Average | 16.87 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -161.73M, while operating income came in at -162.10M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -162.10M |
| Pretax Income | -152.05M |
| Net Income | -152.09M |
| EBITDA | -161.73M |
| EBIT | -162.10M |
| Earnings Per Share (EPS) | -1.43 |
Balance Sheet
Amylyx Pharmaceuticals, Inc. holds 250.76M in cash and equivalents against 5.26M in total debt, resulting in a net debt position of -49.33M. Total book value stands at 239.17M, with working capital of 235.19M providing operational flexibility.
| Cash & Cash Equivalents | 250.76M |
| Total Debt | 5.26M |
| Net Debt | -49.33M |
| Equity (Book Value) | 239.17M |
| Book Value Per Share | 2.15 |
| Working Capital | 235.19M |
Cash Flow
Amylyx Pharmaceuticals, Inc. produced -126.58M in operating cash flow over the past twelve months. After subtracting -140,000.00 in capital expenditures, free cash flow totaled -126.72M - equivalent to -1.19 per share.
| Operating Cash Flow | -126.58M |
| Capital Expenditures | -140,000.00 |
| Free Cash Flow | -126.72M |
| FCF Per Share | -1.19 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -9.80 |
| FCF Yield | -6.63 |
Scores
Amylyx Pharmaceuticals, Inc. posts an Altman Z-Score of 41.87, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 41.87 |